Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

All NewsApril 7, 2026

Merck cuts Terns deal price after TERN-701 data review, while maintaining interest amid competition and CML treatment comparisons.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent